Your session is about to expire
← Back to Search
18F-FMAU PET/CT Imaging for Cancer
N/A
Recruiting
Led By Peter Conti, MD
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Have been diagnosed with a malignancy/tumor/cancer, including but not limited to: brain tumor, breast cancer, lung cancer, esophageal cancer, lymphoma, or sarcoma
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 24 hours after fluorine f 18 d-fmau pet/ct scan
Awards & highlights
Study Summary
This trial is testing a new way to image cancer with PET/CT using a radioactive drug, fluorine F 18 d-FMAU.
Who is the study for?
This trial is for patients with advanced cancers, such as brain, breast, lung, esophageal cancer, lymphoma or sarcoma. Participants must have tumors visible on standard imaging tests and not have had chemotherapy or radiation within the last month. Women who can bear children need a recent negative pregnancy test to join.Check my eligibility
What is being tested?
The trial studies the safety and how well a radioactive drug called fluorine F 18 d-FMAU works in PET/CT scans for detecting cancer spread. It involves injecting this substance and using detailed imaging to locate where it accumulates in the body which may indicate cancer presence.See study design
What are the potential side effects?
As this study focuses on diagnostic imaging rather than treatment, side effects are minimal but may include reactions at the injection site or allergic responses to the radioactive tracer used during PET/CT scanning.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with cancer, such as brain, breast, lung, esophageal cancer, lymphoma, or sarcoma.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 hours after fluorine f 18 d-fmau pet/ct scan
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 hours after fluorine f 18 d-fmau pet/ct scan
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adverse events after injection of fluorine F 18 d-FMAU to the patients
Fluorine F 18 d-FMAU uptake change in tumors post-therapy
Radiation dosimetry of fluorine F 18 d-FMAU
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (fluorine F 18 d-FMAU PET/CT scan)Experimental Treatment3 Interventions
Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
positron emission tomography
2010
Completed Phase 2
~1370
fluorine F 18 d-FMAU
2013
N/A
~20
computed tomography
2010
Completed Phase 2
~1200
Find a Location
Who is running the clinical trial?
University of Southern CaliforniaLead Sponsor
906 Previous Clinical Trials
1,596,258 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,662 Previous Clinical Trials
40,926,043 Total Patients Enrolled
Peter Conti, MDPrincipal InvestigatorUniversity of Southern California
1 Previous Clinical Trials
12 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had chemotherapy or radiation therapy in the last month.I have been diagnosed with cancer, such as brain, breast, lung, esophageal cancer, lymphoma, or sarcoma.I had surgery on the suspected cancer area within the last month.My tumor can be seen on a scan and I had a PET-CT within the last week.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (fluorine F 18 d-FMAU PET/CT scan)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants have been accepted to take part in this research?
"Affirmative. Clinicaltrials.gov upholds that this clinical trial initiated on January 31st, 2014 is actively enrolling participants at the current moment in time. A total of 30 patients must be recruited from 1 medical centre for completion of the study."
Answered by AI
Is this investigation still welcoming participants?
"Affirmative, the clinicaltrials.gov website attests that this experiment is recruiting participants. It was published on January 31st 2014 and last revised on August 5th 2022; 30 individuals are required at a single site for participation."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger